Article info
Electronic pages
Correspondence
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials
- Correspondence to Dr Josefina Durán, Department of Rheumatology, Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile; jgduran{at}uc.cl
Citation
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials
Publication history
- Received April 26, 2016
- Accepted April 29, 2016
- First published May 24, 2016.
Online issue publication
October 31, 2019
Article Versions
- Previous version (31 October 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/